Physician profile
Benjamin Kunze
NPI 1912301334
$666.80
in general payments reported to CMS, 2019-2025
15 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $76.44 · 2023: $139 · 2024: $111 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $107.43 | 2024-2025 | Lithovue, Spaceoar Vue System - 10ml, Ams 700 |
| Astellas Pharma US INC | $91.62 | 2021-2025 | Cresemba |
| Sumitomo Pharma America, INC. | $77.52 | 2023-2024 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $73.46 | 2023-2025 | Pylarify |
| Teleflex LLC | $69.31 | 2024 | Urolift |
| Janssen Pharmaceuticals, INC | $41.33 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.53 | 2022 | |
| Axonics, INC. | $24.56 | 2023 | Bulkamid |
| Vifor Pharma, INC. | $23.05 | 2022 | |
| Legend Biotech USA INC. | $23.00 | 2025 | Carvykti |
| Ethicon US, LLC | $22.26 | 2025 | Echelon; Endopath |
| Abbvie INC. | $21.48 | 2021 | |
| Antares Pharma, INC. | $20.87 | 2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $17.86 | 2022 | |
| Myriad Genetic Laboratories, INC. | $17.52 | 2025 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kunze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.